Jefferies Financial Group Inc. Invests $55,000 in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Jefferies Financial Group Inc. acquired a new position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 53,600 shares of the biopharmaceutical company’s stock, valued at approximately $55,000.

A number of other institutional investors and hedge funds have also bought and sold shares of SGMO. LPL Financial LLC increased its holdings in shares of Sangamo Therapeutics by 113.5% during the 4th quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 16,498 shares during the period. Northern Trust Corp grew its position in Sangamo Therapeutics by 4.5% during the fourth quarter. Northern Trust Corp now owns 398,289 shares of the biopharmaceutical company’s stock worth $406,000 after buying an additional 17,049 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Sangamo Therapeutics by 679.5% during the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 21,793 shares during the period. E Fund Management Co. Ltd. bought a new position in Sangamo Therapeutics during the fourth quarter valued at about $25,000. Finally, PNC Financial Services Group Inc. raised its holdings in Sangamo Therapeutics by 2,319.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 25,000 shares in the last quarter. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ SGMO opened at $0.47 on Monday. Sangamo Therapeutics, Inc. has a 52-week low of $0.30 and a 52-week high of $3.18. The business has a fifty day moving average of $0.73 and a two-hundred day moving average of $1.31. The stock has a market cap of $109.59 million, a PE ratio of -0.63 and a beta of 1.46.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $6.44 million for the quarter, compared to analyst estimates of $7.90 million. Analysts predict that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SGMO. Truist Financial decreased their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Barclays decreased their price target on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 14th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $4.50.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.